Advanced Search

Home > Journals > Minerva Ginecologica > Past Issues > Minerva Ginecologica 2016 October;68(5) > Minerva Ginecologica 2016 October;68(5):557-65

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUEMINERVA GINECOLOGICA

A Journal on Obstetrics and Gynecology

Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index

Frequency: Bi-Monthly

ISSN 0026-4784

Online ISSN 1827-1650

 

Minerva Ginecologica 2016 October;68(5):557-65

HEREDITARY GENITAL AND BREAST CANCER 

    REVIEWS

Breast cancer in BRCA mutation carriers: medical treatment

Andrea MILANI 1, Elena GEUNA 1, Giorgia ZUCCHINI 1, Caterina AVERSA 2, Rossella MARTINELLO 2, Filippo MONTEMURRO 1

1 Investigative Clinical Oncology (INCO), Fondazione del Piemonte per l’Oncologia, Candiolo Cancer Institute (IRCCS), Turin, Italy; 2 University of Turin Medical School, Turin, Italy

About 10% of breast cancers are associated with the inheritance of autosomal dominant breast cancer susceptibility alleles BRCA1 and BRCA2. Until recently, the medical management of BRCA mutation-associated breast cancer has not differed from that of the sporadic breast cancer counterpart. However, there is mounting evidence that this molecular alteration confers sensitivity or resistance to systemic therapies that can be exploited in terms of medical management. For example, studies support the use of platinum salts chemotherapy in BRCA mutated cancers. Moreover, a number of targeted therapies are showing activity in BRCA mutation carriers. Above all, BRCA defective tumor cells are particularly sensitive to Poly(ADP-ribose) polymerase (PARP) inhibitors. This review will summarize the state of the art of the medical treatment of breast cancer in BRCA mutation carriers, with a particular focus on chemotherapies and targeted therapies.

language: English


FULL TEXT  REPRINTS

top of page